NCT02357771View on ClinicalTrials.gov

Probiotic Lozenge Reduce Streptococcus Mutans in Plaque in Orthodontic Bracket Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

September 30, 2015

Conditions
Malocclusion
Interventions
DRUG

Probiotic (L. brevis CD2 lozenges)

Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2

DRUG

Placebo

Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)

Trial Locations (1)

462037

Department of Orthodontics & Dentofacial Orthopaedics, People College Of Dental Sciences & Research Centre, Bhanpur, Bhopal

All Listed Sponsors
collaborator

Peoples University, Bhanpur, Bhopal

OTHER

lead

Next Gen Pharma India Pvt. Ltd.

INDUSTRY

NCT02357771 - Probiotic Lozenge Reduce Streptococcus Mutans in Plaque in Orthodontic Bracket Patients | Biotech Hunter | Biotech Hunter